PA Medical News about amlodipine/valsartan; hypertension

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact
Core Evidence, 08/14/09

Krzesinski J–M et al. – The amlodipine/valsartan combination is an association of two well–known antihypertensive products with specific targets in cardiovascular protection, namely calcium channel blockade and antagonism of the renin–angiotensin–aldosterone system. This kind of association, with neutral metabolic properties and significant antihypertensive efficacy, could be a useful new antihypertensive product. Currently available data have shown that this new combination is well–tolerated and effective even in severe hypertension. Clinical trials are ongoing for further assessment of the efficacy, compliance, and safety of this combination and its congeners. No data exist to prove that the amlodipine/valsartan combination is better than other antihypertensive strategies for cardiovascular or renal protection, but some trials with other combination therapies show such potential advantage.

<< Previous
Review: intranasal mupirocin ointment reduces Staphylococcus...

Next >>
Standard guidelines of care: Lasers for tattoos and pigmented...